Main > HEMATOLOGY > USA. R. PNH>Treat.>C5 Complement>

---

USA. R. PNH>Treat.>C5 Complement>'s subsections
>MAb
Clinical Status: Phase 2 (2019.12.5
Company
Generic Name: Pozelimab
Patent>Assignee; Claims; No.; Etc.
Patent>UpDate: 2022. 06.28
PR Release Web-Site

USA. R. PNH>Treat.>C5 Complement>'s products
This section has no products